Talaris Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update
12 août 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update
14 juin 2021 16h01 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 14, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Upcoming Presentations on FCR001 at the Virtual 2021 American Transplant Congress
03 juin 2021 07h00 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., June 03, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Closing of Initial Public Offering
11 mai 2021 16h01 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to...
Talaris Therapeutics Announces Pricing of Initial Public Offering
06 mai 2021 21h53 HE
|
Talaris Therapeutics, Inc.
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard...